Luiza Ghila
Kenichiro Furuyama
Shane T. Grey
Hanne Scholz
Simona Chera- 1Center for Diabetes Research, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway
- 2Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- 3Immunology Department, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
- 4Faculty of Medicine, St Vincent’s Clinical School, University of New South Wales Sydney, Sydney, NSW, Australia
- 5Hybrid Technology Hub-Centre of Excellence, Faculty of Medicine, University of Oslo, Oslo, Norway
- 6Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Oslo, Norway
Editorial on the Research Topic
Beta-Cell Fate: From Gene Circuits to Disease Mechanisms
Diabetes represents a group of energy metabolism pathologies where the most common forms of the disease exhibit a polygenic and multifactorial aetiology (American Diabetes Association, 2005). Diabetes has truly reached worldwide epidemic proportions with 537 million people living with diabetes worldwide (International Diabetes Federation, 2021). While diabetes can be managed, for many people the onset of life-threatening complications including blindness, kidney failure, heart attacks, stroke, and lower limb amputation further exacerbates the impact on mortality and morbidity (6.7 million deaths related to diabetes complications were reported in 2021). The major difficulty is distinguishing from the plethora of modulations the ones directly responsible for disease initiation. To date it remains largely unknown what are the external factors and cellular signals leading to insulin-producing β-cells decay or dysfunction are and what molecular mechanisms and cellular processes characterize this transition. Identifying the mechanisms governing the onset and progression of these complex conditions is exceedingly challenging, due to their multifactorial environmental component and the intricate genetic susceptibility interaction. Nevertheless, the past decade registered important advances towards understanding these issues. Moreover, the role of the other pancreatic cell populations in the onset, progression, and treatment of diabetes started to be revealed (Chera and Herrera, 2016). These advances contribute towards a more comprehensive demultiplexing of the large diversity of diabetes mechanisms, which is expected to critically contribute to an unambiguous diabetes reclassification.
The aim of this Research Topic was to provide a snapshot of current studies focused on molecular circuits and cellular processes involved in the development, function, and dysfunction of β-cells, touching multiple aspects of islet niche and disease progression.
Molecular Level/Novel Molecular Players
Both T1D and T2D have a complex polygenic and multifactorial aetiology, hence providing a highly variable cellular and molecular readout, even between genetically related individuals. Due to this intrinsic high level of complexity, caused by the overlap between environment and intricate genetic susceptibility, there are still not clearly defined molecular and cellular mechanisms of disease onset and progression. Conversely, monogenic disorders are caused by single gene defects occurring in all cells of the organism. Therefore, the characterization of the causative genes and their associated molecular mechanisms involved in monogenic diabetes onset contribute to understanding the complex non-inherited T1D or T2D disorders.
To date, the genetic predisposition for monogenic diabetes was mostly studied in populations from western countries. To bridge this gap, Zhong et al. analyzed the clinical and genetic characteristics of 200 diabetic patients from Northern China to map the monogenic diabetes prevalence and identify putative novel mutations responsible for MODY. The study pinpointed a heterozygous missense mutation in the coding region of FOXM1 (rs535471991) as a potentially pathogenic variant, most likely affecting the risk of MODY. In the same line, Lin et al. described a case of ABCC8-MODY, previously unreported in China.
Furthermore, by analyzing 160 Egyptian patients, Kassem et al. investigated the correlation between two SERPINB1 SNPs and type 2 diabetes risk. They revealed that SERPINB1 SNP rs152826 can potentially predict glycemic control in diabetic patients while suggesting that the AA genotype of this SNP can be associated with an overall better glycemic regulation. In contrast, the G allele might be a “risk allele” for poor glycemic control.
Although numerous human participants were recruited for genome-wide association studies (GWAS), the genome and environmental factors (lifestyle) variability usually confound datasets, especially when studying a complex trait like blood glucose homeostasis. Hence, meticulous animal model studies are still a critical tool in diabetes research allowing accurate manipulation of both environment and genetic variance. In an original research article, Aga, Hallahan et al. crossed normoglycemic lean inbred DBA mouse with the diabetes-prone New Zealand obese (NZO) strain to identify novel potential T2D genes by using positional cloning. Focused on the most prominent diabetes quantitative trait loci (QTL) Nidd/DBA on chromosome 4, this study identified Kti12, Osbpl9, Ttc39a, and Calr4 as potential T2D candidates.
Interestingly, the associated loci for T1D and T2D seem to be almost completely separated, despite a partially shared phenotype. However, some genes from the risk loci for T1D and T2D might actually interact in common networks in order to mutually regulate crucial pancreatic islet functions. In order to investigate this avenue, Kaur et al. used a dual systems genetics approach by analyzing 57 T1D and 243 T2D established GWAS loci. This study identified a number of novel plausible common candidate genes and pathways for T1D and T2D: nine genes in common T1D and T2D loci that harbor islet eQTLs in linkage disequilibrium with disease-associated variants (GSDMB, CARD9, DNLZ, ERAP1, PPIP5K2, TMEM69, SDCCAG3, PLEKHA1, and HEMK1), and four genes in common T1D and T2D loci mutually regulated by palmitate and cytokines (ASCC2, HIBADH, RASGRP1, and SRGAP2).
Prolonged chronic hyperglycemia is a leading risk factor for developing micro- and macrovascular complications. Interestingly, some individuals do not develop these complications, despite long disease duration suggesting the involvement of protective mechanisms in these patients or, alternatively, the presence of risk factors in the patients that do progress to complications. Keindl et al. studied a panel of inflammatory markers in the plasma of long-term T1D patients with and without vascular complications and found that increased plasma level of a cytokine, soluble interleukin-2 receptor alpha (sIL-2R), was positively associated with the presence of vascular complications.
Cellular Level/Novel Cellular Processes
As also seen above, numerous alleles and mutations associated with increased risk of developing T1D or T2D diabetes (Fuchsberger et al., 2016) were identified in recent years, however cellular fate determination, identity, and function are also regulated at other levels, i.e. mRNA processing or protein folding, packing and sorting. Moss and Sussel summarise in a review the current knowledge on RNA-binding proteins, alternative-splicing events, and transcriptome-wide changes in RNA methylation landscape influencing specific functions of insulin-producing β-cells. As islet cells are mainly secretory cells handling a high amount of hormone production, there is strong pressure on the endoplasmic reticulum (ER) intrinsic folding capacity. This might lead to, for example, misfolded pro-insulin in β-cells triggering a physiological upregulation of the unfolded protein response (UPR) to restore homeostasis. Lenghel et al. discussed recent data addressing the role of UPR on the dedifferentiation or proliferation of β-cells, as well as in triggering inflammation at the islet level, and proposed possible therapies by using UPR for restoring β-cells homeostasis according to their stress level.
Islet Level/Regenerative Strategies
An increasing amount of recent studies suggest that diabetes is not only a β-cell disease, and several other islet cell types could also contribute to its physiopathology (Chakravarthy et al., 2017; Holst et al., 2017; Traub et al., 2017; Brissova et al., 2018; Cigliola et al., 2018; Rorsman and Huising, 2018; Furuyama et al., 2019; Cigliola et al., 2020; Nair et al., 2020). In a mini-review Bru-Tari et al. discussed recent work on islet cell heterogeneity and how this knowledge can be used to restore islet function and therefore to improve current β-cell replacement therapies. An alternative therapeutic strategy could be aimed at increasing the replication rate of insulin-producing β-cells (Nir et al., 2007), which is at very low levels in homeostatic islets. Along these lines, Jiang et al. studied the role of SNAPIN, a protein that interacts with SNARE complexes, in mediating β-cell proliferation. One potential approved drug with β-cell regenerative potential might be liraglutide, an analogue of glucagon-like peptide-1. Villalba et al. investigated the role of liraglutide on the restoration of β-cell mass in regards to neogenesis and transdifferentiation, although additional lineage-tracing studies will be required to clarify the origin of the cells involved in these processes.
Perspectives
A major goal of diabetes research is mapping the diverse specific cellular and molecular mechanisms leading to disease onset and progression. Advances in this area will lead to an improved diabetes classification and a more targeted management of the different diabetes subtypes. The need for this fine-tuned reclassification is clearly illustrated by the current high incidence of diabetes-related complications resulting from insufficient disease models supporting appropriate clinical decision-making. Better disease knowledge and, consequently, its improved management will help avoid unnecessary treatments, improve the patients’ quality of living, reduce costs and ultimately bend the mortality curve.
Thus, in our view, demultiplexing the pathophysiological mechanisms characterising diabetes will remain a key goal of diabetes research, which can be achieved by further 1) mapping associated genetic factors, including the mechanistic characterization and pathogenicity assessment of relevant genetic variants in different ethnic groups; 2) identifying key regulators controlling the cellular processes and molecular landscape leading to disease onset and complications; 3) developing top-notch cell and animal models for studying islet cell function, dysfunction, and extra-pancreatic confounding effects.
Author Contributions
LG and SC drafted the editorial. KF, SG, and HS each contributed by revising and editing. LG, SG, HS, and SC handled the received manuscripts. All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.
Funding
This work was supported by funds from the Research Council of Norway (NFR 247577 (SC), 251041 (SC) and 314397 (SC); CoE 262613 (HS)); Novo Nordic Foundation (NNF15OC0015054 and NNF21OC0067325) to SC; Diabetesforbundets forskningsfond to LG, SC, and HS.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We are grateful to the editors, authors, and reviewers for their contribution emphasizing new research avenues in this rapidly changing and challenging field.
References
American Diabetes Association (2005). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 28 Suppl 1, S37–S42. doi:10.2337/diacare.28.suppl_1.s37
Brissova, M., Haliyur, R., Saunders, D., Shrestha, S., Dai, C., Blodgett, D. M., et al. (2018). α Cell Function and Gene Expression Are Compromised in Type 1 Diabetes. Cel Rep. 22 (10), 2667–2676. doi:10.1016/j.celrep.2018.02.032
Chakravarthy, H., Gu, X., Enge, M., Dai, X., Wang, Y., Damond, N., et al. (2017). Converting Adult Pancreatic Islet α Cells into β Cells by Targeting Both Dnmt1 and Arx. Cel Metab. 25 (3), 622–634. doi:10.1016/j.cmet.2017.01.009
Chera, S., and Herrera, P. L. (2016). Regeneration of Pancreatic Insulin-Producing Cells by In Situ Adaptive Cell Conversion. Curr. Opin. Genet. Dev. 40, 1–10. doi:10.1016/j.gde.2016.05.010
Cigliola, V., Ghila, L., Thorel, F., van Gurp, L., Baronnier, D., Oropeza, D., et al. (2018). Pancreatic Islet-Autonomous Insulin and Smoothened-Mediated Signalling Modulate Identity Changes of Glucagon+ α-cells. Nat. Cel Biol. 20 (11), 1267–1277. doi:10.1038/s41556-018-0216-y
Cigliola, V., Ghila, L., Chera, S., and Herrera, P. L. (2020). Tissue Repair Brakes: A Common Paradigm in the Biology of Regeneration. Stem Cells 38 (3), 330–339. doi:10.1002/stem.3118
Fuchsberger, C., Flannick, J., Teslovich, T. M., Mahajan, A., Agarwala, V., Gaulton, K. J., et al. (2016). The Genetic Architecture of Type 2 Diabetes. Nature 536 (7614), 41–47. doi:10.1038/nature18642
Furuyama, K., Chera, S., van Gurp, L., Oropeza, D., Ghila, L., Damond, N., et al. (2019). Diabetes Relief in Mice by Glucose-Sensing Insulin-Secreting Human α-cells. Nature 567 (7746), 43–48. doi:10.1038/s41586-019-0942-8
Holst, J. J., Holland, W., Gromada, J., Lee, Y., Unger, R. H., Yan, H., et al. (2017). Insulin and Glucagon: Partners for Life. Endocrinology 158 (4), 696–701. doi:10.1210/en.2016-1748
International Diabetes Federation (2021). IDF Diabetes Atlas. 10th Edn. Brussels, Belgium: International Diabetes Federation.
Nair, G. G., Tzanakakis, E. S., and Hebrok, M. (2020). Emerging Routes to the Generation of Functional β-cells for Diabetes Mellitus Cell Therapy. Nat. Rev. Endocrinol. 16 (9), 506–518. doi:10.1038/s41574-020-0375-3
Nir, T., Melton, D. A., and Dor, Y. (2007). Recovery from Diabetes in Mice by β Cell Regeneration. J. Clin. Invest. 117 (9), 2553–2561. doi:10.1172/JCI32959
Rorsman, P., and Huising, M. O. (2018). The Somatostatin-Secreting Pancreatic δ-Cell in Health and Disease. Nat. Rev. Endocrinol. 14 (7), 404–414. doi:10.1038/s41574-018-0020-6
Keywords: MODY (mature onset diabetes of the young), T1D (type 1 diabetes), T2D (type 2 diabetes), mRNA processing, UPR stress, islet heterogeneity, cell reprogramming
Citation: Ghila L, Furuyama K, Grey ST, Scholz H and Chera S (2022) Editorial: Beta-Cell Fate: From Gene Circuits to Disease Mechanisms. Front. Genet. 13:822440. doi: 10.3389/fgene.2022.822440
Received: 25 November 2021; Accepted: 04 February 2022;
Published: 25 February 2022.
Edited and Reviewed by:
Jordi Pérez-Tur, Spanish National Research Council (CSIC), SpainCopyright © 2022 Ghila, Furuyama, Grey, Scholz and Chera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luiza Ghila, bHVpemEuZ2hpbGFAdWliLm5v; Simona Chera, c2ltb25hLmNoZXJhQHVpYi5ubw==